Q-omics provides the consensus-scored TRAFD1 profile across patient tissues and cancer cell-line models. TRAFD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAFD1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRAFD1 protein abundance shows 24,887 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight SKCM, KIRC, and CCRCC as cancer lineages where TRAFD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAFD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAFD1 survival associations across molecular data types. TRAFD1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAFD1 RNA expression–survival associations across cancer types. High TRAFD1 expression shows unfavorable associations in LIHC and UVM, but favorable associations in SKCM, CESC, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAFD1 RNA expression.
This table summarizes TRAFD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAFD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAFD1 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, BRCA, HNSC and BLCA. The KIRC box plot shows higher TRAFD1 RNA expression in tumor versus normal tissue (log2 FC = +0.893, t-test p < 0.001).
This table shows molecular features associated with TRAFD1 in patient tissues and cancer cell lines. In patient samples, TRAFD1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAFD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
